Two vaccines that could protect against a potentially deadly strain of meningitis not covered by current shots have been sent for review by federal regulators Drugmakers Novartis and Pfizer announced Tuesday that theyve each submitted applications to the Food and Drug Administration for vaccines aimed at preventing meningitis B infections like those that sparked outbreaks last year at   Current vaccines cover four strains of bacterial meningitis but not strain B The move drew immediate praise from advocates like Alicia Stillman of West Bloomfield Michigan whose yearold daughter died last year from a fastmoving meningitis B infection Since then Stillman has begun  where the vaccine is available to help protect others I am excited but still cautious as I know nothing happens fast in that world Stillman said Tuesday Meningitis infections affect about  people in the US each year including about  percent caused by the B strain Though theyre rare  about  percent of those who fall ill and leave  percent with devastating side effects The prospective vaccines Novartis Bexsero and Pfizers bivalent rLP were granted breakthrough therapy status by the FDA earlier this year in a move that could speed up consideration of the drugs If approval is granted it could take months before the vaccines are available for consumers Novartis Bexsero was granted emergency use status at Princeton University and the University of California Santa Barbara and is already approved in Europe Canada and Australia Development of a vaccine has been  years in the making because meningitis B is much harder to target than other strains said Dr Andrin Oswald head of Novartis vaccine division Bexsero protects only against meningitis B but Novartis has a combination vaccine in development Its clearly the vaccine that makes the most sense Oswald told NBC News For most parents they want to protect their children and teenagers with one shot